What is the primary pathophysiology of hemorrhagic stroke?

Pathophysiology of Hemorrhagic Stroke

Hemorrhagic stroke injures brain tissue through two distinct mechanisms: direct mechanical damage from the expanding hematoma and secondary injury cascades triggered by blood degradation products, with both processes occurring over different time scales and offering distinct therapeutic targets. 1

Primary Injury Mechanisms

Direct Mechanical Damage

The initial hemorrhage causes immediate brain injury through several pressure-related mechanisms 1:

• Local tissue compression from the acutely expanding mass lesion directly damages surrounding brain parenchyma 1
• Increased intracranial pressure (ICP) produces widespread mechanical injury beyond the immediate hemorrhage site 1
• Hydrocephalus develops when blood obstructs cerebrospinal fluid pathways, particularly with intraventricular extension 1
• Herniation syndromes occur when mass effect displaces brain structures across compartmental boundaries 1

Hematoma Expansion

Approximately one-third of patients experience substantial hematoma expansion within the first few hours after hemorrhage onset 1:

• Early hematoma expansion is driven by mechanical shearing of surrounding vessels by the initial hematoma 1
• Timing critically influences expansion frequency—presentation within the first few hours carries higher likelihood of expansion 1
• Hematoma volume and expansion are powerful independent predictors of death and disability 1

Secondary Injury Mechanisms

Blood Product Toxicity

Unlike the immediate mechanical injury, secondary damage unfolds over hours to weeks through distinct pathophysiological cascades 1:

• Hemolysis of red blood cells releases hemoglobin and iron into the brain parenchyma 1
• Thrombin production from the clotting cascade contributes to cellular toxicity 1
• Blood degradation products exert direct neurotoxic effects on surrounding viable tissue 1

Inflammatory Response

Hemorrhage triggers robust inflammatory cascades that amplify tissue injury 2:

• Brain-resident immune cells (microglia and astrocytes) become activated immediately after hemorrhage 2
• Peripheral leukocyte infiltration occurs within hours, contributing to both tissue injury and potential recovery 2
• Cytokine release propagates the inflammatory response throughout the affected territory 2

Cerebral Edema

Perihematomal edema (PHE) represents a radiological marker of secondary injury 1:

• Blood-brain barrier disruption allows fluid extravasation into surrounding tissue 1
• PHE develops over hours to days and serves as a therapeutic target in phase II trials 1
• Edema contributes to mass effect independent of the hematoma itself 1

Underlying Vascular Pathologies

Small Vessel Disease Subtypes

Primary intracerebral hemorrhage results from two distinct age-related cerebral small vessel pathologies 1:

Arteriolosclerosis (Lipohyalinosis):

• Affects penetrating arterioles of basal ganglia, thalamus, brainstem, and deep cerebellar nuclei 1
• Characterized by concentric hyalinized vascular wall thickening 1
• Major risk factors include hypertension, diabetes, and age 1
• Produces hemorrhages in deep brain territories 1

Cerebral Amyloid Angiopathy (CAA):

• Involves β-amyloid peptide deposition in arteriole and capillary walls 1
• Affects leptomeninges, cerebral cortex, and cerebellar hemispheres (lobar territories) 1
• Primary risk factors are age and apolipoprotein E ε2 or ε4 alleles 1
• Produces hemorrhages in lobar brain regions 1

Both pathologies appear at moderate to severe extents in 30-35% of individuals in longitudinal aging studies, though only a small subset develops clinical hemorrhage 1.

Distinction from Ischemic Stroke

Fundamental Pathophysiological Differences

Hemorrhagic stroke differs fundamentally from ischemic stroke in therapeutic objectives 1:

• Primary goal in ischemic stroke is to resuscitate penumbral tissue and minimize disability 1
• Primary goal in hemorrhagic stroke is to prevent rapid deterioration and early death 1
• Therapeutic time windows may be steeper for hematoma expansion than for ischemic reperfusion, but secondary injury mechanisms provide opportunities for wider therapeutic windows 1

Clinical Implications

The distinct pathophysiology translates to different clinical priorities 1:

• High case fatality and morbidity limit available trial participants compared to ischemic stroke 1
• Early withdrawal-of-treatment occurs more frequently due to severity 1
• Global burden is higher particularly in low- and middle-income countries, with greater loss of productive life years 1

Therapeutic Target Windows

The dual-mechanism injury pattern creates distinct therapeutic opportunities 1:

• Ultra-early interventions (first hours) target hematoma expansion through blood pressure control and anticoagulation reversal 1
• Early-to-intermediate interventions (hours to days) address surgical evacuation and mass effect reduction 1
• Subacute interventions (days to weeks) target secondary injury mechanisms including inflammation, edema, and blood product toxicity 1